nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2D6—Fingolimod—multiple sclerosis	0.0481	0.167	CbGbCtD
Bortezomib—CYP1A1—Dexamethasone—multiple sclerosis	0.0319	0.111	CbGbCtD
Bortezomib—CYP3A4—Fingolimod—multiple sclerosis	0.0306	0.106	CbGbCtD
Bortezomib—CYP2C19—Prednisone—multiple sclerosis	0.0247	0.0859	CbGbCtD
Bortezomib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0197	0.0686	CbGbCtD
Bortezomib—CYP2C8—Dexamethasone—multiple sclerosis	0.0184	0.0639	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—multiple sclerosis	0.0154	0.0536	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—multiple sclerosis	0.0149	0.052	CbGbCtD
Bortezomib—CYP3A4—Mitoxantrone—multiple sclerosis	0.0144	0.05	CbGbCtD
Bortezomib—CYP2C9—Dexamethasone—multiple sclerosis	0.0128	0.0446	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—multiple sclerosis	0.0128	0.0446	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—multiple sclerosis	0.0127	0.044	CbGbCtD
Bortezomib—CYP3A4—Prednisone—multiple sclerosis	0.0119	0.0415	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—multiple sclerosis	0.0117	0.0408	CbGbCtD
Bortezomib—CYP3A4—Dexamethasone—multiple sclerosis	0.00746	0.0259	CbGbCtD
Bortezomib—PSMD1—retina—multiple sclerosis	0.00411	0.0432	CbGeAlD
Bortezomib—PSMD2—retina—multiple sclerosis	0.00364	0.0383	CbGeAlD
Bortezomib—PSMD1—medulla oblongata—multiple sclerosis	0.00297	0.0312	CbGeAlD
Bortezomib—PSMB2—retina—multiple sclerosis	0.00272	0.0287	CbGeAlD
Bortezomib—PSMD1—midbrain—multiple sclerosis	0.00271	0.0286	CbGeAlD
Bortezomib—PSMA1—nervous system—multiple sclerosis	0.00266	0.028	CbGeAlD
Bortezomib—PSMD1—spinal cord—multiple sclerosis	0.00265	0.0279	CbGeAlD
Bortezomib—PSMD2—medulla oblongata—multiple sclerosis	0.00263	0.0277	CbGeAlD
Bortezomib—PSMA1—central nervous system—multiple sclerosis	0.00256	0.0269	CbGeAlD
Bortezomib—PSMA1—cerebellum—multiple sclerosis	0.0025	0.0263	CbGeAlD
Bortezomib—PSMD2—midbrain—multiple sclerosis	0.0024	0.0253	CbGeAlD
Bortezomib—PSMD2—spinal cord—multiple sclerosis	0.00235	0.0247	CbGeAlD
Bortezomib—PSMB5—medulla oblongata—multiple sclerosis	0.00231	0.0243	CbGeAlD
Bortezomib—PSMB5—midbrain—multiple sclerosis	0.00211	0.0222	CbGeAlD
Bortezomib—PSMD1—cerebellum—multiple sclerosis	0.0021	0.0221	CbGeAlD
Bortezomib—PSMB5—spinal cord—multiple sclerosis	0.00206	0.0217	CbGeAlD
Bortezomib—PSMA1—brain—multiple sclerosis	0.00203	0.0214	CbGeAlD
Bortezomib—PSMB1—medulla oblongata—multiple sclerosis	0.00202	0.0212	CbGeAlD
Bortezomib—PSMD2—nervous system—multiple sclerosis	0.00198	0.0208	CbGeAlD
Bortezomib—PSMB2—medulla oblongata—multiple sclerosis	0.00197	0.0207	CbGeAlD
Bortezomib—Nateglinide—SLC15A2—multiple sclerosis	0.00192	0.823	CrCbGaD
Bortezomib—PSMD2—central nervous system—multiple sclerosis	0.0019	0.02	CbGeAlD
Bortezomib—PSMD2—cerebellum—multiple sclerosis	0.00186	0.0196	CbGeAlD
Bortezomib—PSMB1—midbrain—multiple sclerosis	0.00184	0.0194	CbGeAlD
Bortezomib—PSMB2—midbrain—multiple sclerosis	0.0018	0.0189	CbGeAlD
Bortezomib—PSMB1—spinal cord—multiple sclerosis	0.0018	0.0189	CbGeAlD
Bortezomib—PSMB2—spinal cord—multiple sclerosis	0.00176	0.0185	CbGeAlD
Bortezomib—SLC31A1—medulla oblongata—multiple sclerosis	0.00171	0.0179	CbGeAlD
Bortezomib—PSMD1—brain—multiple sclerosis	0.00171	0.0179	CbGeAlD
Bortezomib—PSMB5—cerebellum—multiple sclerosis	0.00163	0.0172	CbGeAlD
Bortezomib—SLC31A1—midbrain—multiple sclerosis	0.00156	0.0164	CbGeAlD
Bortezomib—SLC31A1—spinal cord—multiple sclerosis	0.00152	0.016	CbGeAlD
Bortezomib—PSMB1—nervous system—multiple sclerosis	0.00152	0.016	CbGeAlD
Bortezomib—PSMD2—brain—multiple sclerosis	0.00151	0.0159	CbGeAlD
Bortezomib—PSMB8—brain—multiple sclerosis	0.0015	0.0158	CbGeAlD
Bortezomib—PSMB2—nervous system—multiple sclerosis	0.00148	0.0156	CbGeAlD
Bortezomib—PSMB1—central nervous system—multiple sclerosis	0.00146	0.0154	CbGeAlD
Bortezomib—PSMB1—cerebellum—multiple sclerosis	0.00143	0.015	CbGeAlD
Bortezomib—PSMB2—central nervous system—multiple sclerosis	0.00142	0.015	CbGeAlD
Bortezomib—PSMB2—cerebellum—multiple sclerosis	0.00139	0.0147	CbGeAlD
Bortezomib—PSMB5—brain—multiple sclerosis	0.00133	0.014	CbGeAlD
Bortezomib—SLC31A1—nervous system—multiple sclerosis	0.00128	0.0135	CbGeAlD
Bortezomib—SLC31A1—central nervous system—multiple sclerosis	0.00123	0.013	CbGeAlD
Bortezomib—SLC31A1—cerebellum—multiple sclerosis	0.00121	0.0127	CbGeAlD
Bortezomib—PSMB1—brain—multiple sclerosis	0.00116	0.0122	CbGeAlD
Bortezomib—PSMB2—brain—multiple sclerosis	0.00113	0.0119	CbGeAlD
Bortezomib—SLC31A1—brain—multiple sclerosis	0.000979	0.0103	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Cladribine—multiple sclerosis	0.000879	0.113	CbGdCrCtD
Bortezomib—CYP2D6—brainstem—multiple sclerosis	0.0006	0.00631	CbGeAlD
Bortezomib—PTGS1—spinal cord—multiple sclerosis	0.000454	0.00478	CbGeAlD
Bortezomib—CYP1A1—nervous system—multiple sclerosis	0.000435	0.00458	CbGeAlD
Bortezomib—CYP1A1—central nervous system—multiple sclerosis	0.000419	0.00441	CbGeAlD
Bortezomib—Nateglinide—ALB—multiple sclerosis	0.000414	0.177	CrCbGaD
Bortezomib—PTGS1—nervous system—multiple sclerosis	0.000382	0.00402	CbGeAlD
Bortezomib—PTGS1—central nervous system—multiple sclerosis	0.000368	0.00387	CbGeAlD
Bortezomib—CYP2C8—brain—multiple sclerosis	0.00036	0.00379	CbGeAlD
Bortezomib—CYP1A1—brain—multiple sclerosis	0.000333	0.0035	CbGeAlD
Bortezomib—PSMD2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000332	0.0429	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Methylprednisolone—multiple sclerosis	0.00033	0.0426	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000327	0.0422	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000327	0.0422	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000319	0.0412	CbGdCrCtD
Bortezomib—CYP3A4—nervous system—multiple sclerosis	0.000319	0.00336	CbGeAlD
Bortezomib—CYP2D6—nervous system—multiple sclerosis	0.000314	0.00331	CbGeAlD
Bortezomib—CYP3A4—central nervous system—multiple sclerosis	0.000307	0.00324	CbGeAlD
Bortezomib—CYP2D6—central nervous system—multiple sclerosis	0.000303	0.00318	CbGeAlD
Bortezomib—CYP2D6—cerebellum—multiple sclerosis	0.000296	0.00311	CbGeAlD
Bortezomib—PSMB8—Medrysone—Prednisolone—multiple sclerosis	0.000294	0.038	CbGdCrCtD
Bortezomib—PTGS1—brain—multiple sclerosis	0.000292	0.00308	CbGeAlD
Bortezomib—CYP2D6—brain—multiple sclerosis	0.00024	0.00253	CbGeAlD
Bortezomib—PSMB8—Fluorometholone—Methylprednisolone—multiple sclerosis	0.000239	0.0309	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—multiple sclerosis	0.000235	0.0304	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—multiple sclerosis	0.000235	0.0304	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—multiple sclerosis	0.00023	0.0297	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisone—multiple sclerosis	0.000218	0.0282	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—multiple sclerosis	0.000213	0.0275	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Methylprednisolone—multiple sclerosis	0.000182	0.0235	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—multiple sclerosis	0.000179	0.0231	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Betamethasone—multiple sclerosis	0.000179	0.0231	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—multiple sclerosis	0.000175	0.0226	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Methylprednisolone—multiple sclerosis	0.000168	0.0217	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000168	0.0217	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisone—multiple sclerosis	0.000166	0.0214	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—multiple sclerosis	0.000166	0.0214	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—multiple sclerosis	0.000166	0.0214	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—multiple sclerosis	0.000162	0.0209	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—multiple sclerosis	0.000162	0.0209	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—multiple sclerosis	0.000162	0.0209	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—multiple sclerosis	0.000154	0.0198	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—multiple sclerosis	0.000154	0.0198	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—multiple sclerosis	0.00015	0.0193	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—multiple sclerosis	0.00015	0.0193	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Methylprednisolone—multiple sclerosis	9.77e-05	0.0126	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Methylprednisolone—multiple sclerosis	9.77e-05	0.0126	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—multiple sclerosis	9.62e-05	0.0124	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—multiple sclerosis	9.62e-05	0.0124	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—multiple sclerosis	9.4e-05	0.0121	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—multiple sclerosis	9.4e-05	0.0121	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—multiple sclerosis	8.92e-05	0.0115	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—multiple sclerosis	8.92e-05	0.0115	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—multiple sclerosis	8.7e-05	0.0112	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—multiple sclerosis	8.7e-05	0.0112	CbGdCrCtD
Bortezomib—Tachycardia—Triamcinolone—multiple sclerosis	8.47e-05	0.000227	CcSEcCtD
Bortezomib—Mental disorder—Prednisone—multiple sclerosis	8.46e-05	0.000227	CcSEcCtD
Bortezomib—Nausea—Azathioprine—multiple sclerosis	8.45e-05	0.000227	CcSEcCtD
Bortezomib—Tachycardia—Methylprednisolone—multiple sclerosis	8.45e-05	0.000227	CcSEcCtD
Bortezomib—Skin disorder—Methylprednisolone—multiple sclerosis	8.41e-05	0.000226	CcSEcCtD
Bortezomib—Erythema—Prednisone—multiple sclerosis	8.4e-05	0.000226	CcSEcCtD
Bortezomib—Malnutrition—Prednisone—multiple sclerosis	8.4e-05	0.000226	CcSEcCtD
Bortezomib—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.39e-05	0.000225	CcSEcCtD
Bortezomib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.37e-05	0.000225	CcSEcCtD
Bortezomib—Convulsion—Dexamethasone—multiple sclerosis	8.36e-05	0.000224	CcSEcCtD
Bortezomib—Convulsion—Betamethasone—multiple sclerosis	8.36e-05	0.000224	CcSEcCtD
Bortezomib—Hypertension—Betamethasone—multiple sclerosis	8.33e-05	0.000224	CcSEcCtD
Bortezomib—Hypertension—Dexamethasone—multiple sclerosis	8.33e-05	0.000224	CcSEcCtD
Bortezomib—Asthenia—Mitoxantrone—multiple sclerosis	8.25e-05	0.000222	CcSEcCtD
Bortezomib—Myalgia—Dexamethasone—multiple sclerosis	8.21e-05	0.000221	CcSEcCtD
Bortezomib—Myalgia—Betamethasone—multiple sclerosis	8.21e-05	0.000221	CcSEcCtD
Bortezomib—Anxiety—Dexamethasone—multiple sclerosis	8.19e-05	0.00022	CcSEcCtD
Bortezomib—Anxiety—Betamethasone—multiple sclerosis	8.19e-05	0.00022	CcSEcCtD
Bortezomib—Discomfort—Betamethasone—multiple sclerosis	8.12e-05	0.000218	CcSEcCtD
Bortezomib—Discomfort—Dexamethasone—multiple sclerosis	8.12e-05	0.000218	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—multiple sclerosis	8.11e-05	0.000218	CcSEcCtD
Bortezomib—Hypotension—Methylprednisolone—multiple sclerosis	8.09e-05	0.000217	CcSEcCtD
Bortezomib—Pain—Prednisolone—multiple sclerosis	8.07e-05	0.000217	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—multiple sclerosis	8.07e-05	0.000217	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—multiple sclerosis	8.07e-05	0.000217	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—multiple sclerosis	7.97e-05	0.000214	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—multiple sclerosis	7.92e-05	0.000213	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—multiple sclerosis	7.91e-05	0.000212	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	7.91e-05	0.000212	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	7.89e-05	0.000212	CcSEcCtD
Bortezomib—Anaphylactic shock—Betamethasone—multiple sclerosis	7.87e-05	0.000211	CcSEcCtD
Bortezomib—Oedema—Betamethasone—multiple sclerosis	7.87e-05	0.000211	CcSEcCtD
Bortezomib—Oedema—Dexamethasone—multiple sclerosis	7.87e-05	0.000211	CcSEcCtD
Bortezomib—Anaphylactic shock—Dexamethasone—multiple sclerosis	7.87e-05	0.000211	CcSEcCtD
Bortezomib—Diarrhoea—Mitoxantrone—multiple sclerosis	7.87e-05	0.000211	CcSEcCtD
Bortezomib—Insomnia—Triamcinolone—multiple sclerosis	7.85e-05	0.000211	CcSEcCtD
Bortezomib—Insomnia—Methylprednisolone—multiple sclerosis	7.83e-05	0.00021	CcSEcCtD
Bortezomib—Infection—Dexamethasone—multiple sclerosis	7.82e-05	0.00021	CcSEcCtD
Bortezomib—Infection—Betamethasone—multiple sclerosis	7.82e-05	0.00021	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisone—multiple sclerosis	7.8e-05	0.000209	CcSEcCtD
Bortezomib—Paraesthesia—Triamcinolone—multiple sclerosis	7.79e-05	0.000209	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisolone—multiple sclerosis	7.78e-05	0.000209	CcSEcCtD
Bortezomib—Paraesthesia—Methylprednisolone—multiple sclerosis	7.78e-05	0.000209	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—multiple sclerosis	7.77e-05	0.000209	CcSEcCtD
Bortezomib—Anaemia—Prednisone—multiple sclerosis	7.77e-05	0.000208	CcSEcCtD
Bortezomib—Shock—Dexamethasone—multiple sclerosis	7.75e-05	0.000208	CcSEcCtD
Bortezomib—Shock—Betamethasone—multiple sclerosis	7.75e-05	0.000208	CcSEcCtD
Bortezomib—Dyspnoea—Triamcinolone—multiple sclerosis	7.74e-05	0.000208	CcSEcCtD
Bortezomib—Nervous system disorder—Dexamethasone—multiple sclerosis	7.72e-05	0.000207	CcSEcCtD
Bortezomib—Nervous system disorder—Betamethasone—multiple sclerosis	7.72e-05	0.000207	CcSEcCtD
Bortezomib—Agitation—Prednisone—multiple sclerosis	7.72e-05	0.000207	CcSEcCtD
Bortezomib—Thrombocytopenia—Dexamethasone—multiple sclerosis	7.71e-05	0.000207	CcSEcCtD
Bortezomib—Thrombocytopenia—Betamethasone—multiple sclerosis	7.71e-05	0.000207	CcSEcCtD
Bortezomib—Tachycardia—Betamethasone—multiple sclerosis	7.69e-05	0.000206	CcSEcCtD
Bortezomib—Tachycardia—Dexamethasone—multiple sclerosis	7.69e-05	0.000206	CcSEcCtD
Bortezomib—Angioedema—Prednisone—multiple sclerosis	7.68e-05	0.000206	CcSEcCtD
Bortezomib—Dyspepsia—Triamcinolone—multiple sclerosis	7.64e-05	0.000205	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—multiple sclerosis	7.63e-05	0.000205	CcSEcCtD
Bortezomib—Dyspepsia—Methylprednisolone—multiple sclerosis	7.62e-05	0.000205	CcSEcCtD
Bortezomib—Hyperhidrosis—Dexamethasone—multiple sclerosis	7.61e-05	0.000204	CcSEcCtD
Bortezomib—Hyperhidrosis—Betamethasone—multiple sclerosis	7.61e-05	0.000204	CcSEcCtD
Bortezomib—Malaise—Prednisone—multiple sclerosis	7.58e-05	0.000203	CcSEcCtD
Bortezomib—Vertigo—Prednisone—multiple sclerosis	7.55e-05	0.000203	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—multiple sclerosis	7.54e-05	0.000202	CcSEcCtD
Bortezomib—Syncope—Prednisone—multiple sclerosis	7.54e-05	0.000202	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—multiple sclerosis	7.52e-05	0.000202	CcSEcCtD
Bortezomib—Anorexia—Betamethasone—multiple sclerosis	7.51e-05	0.000201	CcSEcCtD
Bortezomib—Anorexia—Dexamethasone—multiple sclerosis	7.51e-05	0.000201	CcSEcCtD
Bortezomib—Urticaria—Prednisolone—multiple sclerosis	7.5e-05	0.000201	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—multiple sclerosis	7.49e-05	0.000201	CcSEcCtD
Bortezomib—Fatigue—Triamcinolone—multiple sclerosis	7.48e-05	0.000201	CcSEcCtD
Bortezomib—Fatigue—Methylprednisolone—multiple sclerosis	7.47e-05	0.0002	CcSEcCtD
Bortezomib—Pain—Triamcinolone—multiple sclerosis	7.42e-05	0.000199	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—multiple sclerosis	7.38e-05	0.000198	CcSEcCtD
Bortezomib—Hypotension—Betamethasone—multiple sclerosis	7.36e-05	0.000198	CcSEcCtD
Bortezomib—Hypotension—Dexamethasone—multiple sclerosis	7.36e-05	0.000198	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—multiple sclerosis	7.32e-05	0.000196	CcSEcCtD
Bortezomib—Vomiting—Mitoxantrone—multiple sclerosis	7.31e-05	0.000196	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—multiple sclerosis	7.29e-05	0.000196	CcSEcCtD
Bortezomib—Convulsion—Prednisone—multiple sclerosis	7.28e-05	0.000195	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—multiple sclerosis	7.27e-05	0.000195	CcSEcCtD
Bortezomib—Hypertension—Prednisone—multiple sclerosis	7.25e-05	0.000195	CcSEcCtD
Bortezomib—Rash—Mitoxantrone—multiple sclerosis	7.25e-05	0.000195	CcSEcCtD
Bortezomib—Dermatitis—Mitoxantrone—multiple sclerosis	7.25e-05	0.000195	CcSEcCtD
Bortezomib—Chills—Methotrexate—multiple sclerosis	7.24e-05	0.000194	CcSEcCtD
Bortezomib—Headache—Mitoxantrone—multiple sclerosis	7.21e-05	0.000193	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.17e-05	0.000193	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.17e-05	0.000193	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—multiple sclerosis	7.15e-05	0.000192	CcSEcCtD
Bortezomib—Myalgia—Prednisone—multiple sclerosis	7.15e-05	0.000192	CcSEcCtD
Bortezomib—Feeling abnormal—Triamcinolone—multiple sclerosis	7.15e-05	0.000192	CcSEcCtD
Bortezomib—Feeling abnormal—Methylprednisolone—multiple sclerosis	7.14e-05	0.000192	CcSEcCtD
Bortezomib—Anxiety—Prednisone—multiple sclerosis	7.13e-05	0.000191	CcSEcCtD
Bortezomib—Insomnia—Dexamethasone—multiple sclerosis	7.12e-05	0.000191	CcSEcCtD
Bortezomib—Insomnia—Betamethasone—multiple sclerosis	7.12e-05	0.000191	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	7.1e-05	0.000191	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.08e-05	0.00019	CcSEcCtD
Bortezomib—Paraesthesia—Dexamethasone—multiple sclerosis	7.07e-05	0.00019	CcSEcCtD
Bortezomib—Paraesthesia—Betamethasone—multiple sclerosis	7.07e-05	0.00019	CcSEcCtD
Bortezomib—Discomfort—Prednisone—multiple sclerosis	7.07e-05	0.00019	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—multiple sclerosis	7.07e-05	0.00019	CcSEcCtD
Bortezomib—Erythema—Methotrexate—multiple sclerosis	7.02e-05	0.000189	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—multiple sclerosis	7.02e-05	0.000189	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisolone—multiple sclerosis	6.95e-05	0.000187	CcSEcCtD
Bortezomib—Dyspepsia—Dexamethasone—multiple sclerosis	6.93e-05	0.000186	CcSEcCtD
Bortezomib—Dyspepsia—Betamethasone—multiple sclerosis	6.93e-05	0.000186	CcSEcCtD
Bortezomib—Urticaria—Triamcinolone—multiple sclerosis	6.89e-05	0.000185	CcSEcCtD
Bortezomib—Urticaria—Methylprednisolone—multiple sclerosis	6.88e-05	0.000185	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—multiple sclerosis	6.88e-05	0.000185	CcSEcCtD
Bortezomib—Body temperature increased—Triamcinolone—multiple sclerosis	6.86e-05	0.000184	CcSEcCtD
Bortezomib—Oedema—Prednisone—multiple sclerosis	6.86e-05	0.000184	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—multiple sclerosis	6.86e-05	0.000184	CcSEcCtD
Bortezomib—Abdominal pain—Methylprednisolone—multiple sclerosis	6.85e-05	0.000184	CcSEcCtD
Bortezomib—Decreased appetite—Dexamethasone—multiple sclerosis	6.85e-05	0.000184	CcSEcCtD
Bortezomib—Decreased appetite—Betamethasone—multiple sclerosis	6.85e-05	0.000184	CcSEcCtD
Bortezomib—Nausea—Mitoxantrone—multiple sclerosis	6.83e-05	0.000183	CcSEcCtD
Bortezomib—Infection—Prednisone—multiple sclerosis	6.81e-05	0.000183	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	6.8e-05	0.000182	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	6.8e-05	0.000182	CcSEcCtD
Bortezomib—Back pain—Methotrexate—multiple sclerosis	6.79e-05	0.000182	CcSEcCtD
Bortezomib—Fatigue—Betamethasone—multiple sclerosis	6.79e-05	0.000182	CcSEcCtD
Bortezomib—Fatigue—Dexamethasone—multiple sclerosis	6.79e-05	0.000182	CcSEcCtD
Bortezomib—Shock—Prednisone—multiple sclerosis	6.75e-05	0.000181	CcSEcCtD
Bortezomib—Pain—Betamethasone—multiple sclerosis	6.73e-05	0.000181	CcSEcCtD
Bortezomib—Pain—Dexamethasone—multiple sclerosis	6.73e-05	0.000181	CcSEcCtD
Bortezomib—Nervous system disorder—Prednisone—multiple sclerosis	6.72e-05	0.000181	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—multiple sclerosis	6.69e-05	0.00018	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—multiple sclerosis	6.66e-05	0.000179	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisone—multiple sclerosis	6.63e-05	0.000178	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—multiple sclerosis	6.62e-05	0.000178	CcSEcCtD
Bortezomib—Anorexia—Prednisone—multiple sclerosis	6.54e-05	0.000175	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—multiple sclerosis	6.52e-05	0.000175	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—multiple sclerosis	6.49e-05	0.000174	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—multiple sclerosis	6.49e-05	0.000174	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—multiple sclerosis	6.49e-05	0.000174	CcSEcCtD
Bortezomib—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.44e-05	0.000173	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.44e-05	0.000173	CcSEcCtD
Bortezomib—Hypersensitivity—Triamcinolone—multiple sclerosis	6.39e-05	0.000172	CcSEcCtD
Bortezomib—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.38e-05	0.000171	CcSEcCtD
Bortezomib—Malaise—Methotrexate—multiple sclerosis	6.33e-05	0.00017	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—multiple sclerosis	6.31e-05	0.000169	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—multiple sclerosis	6.29e-05	0.000169	CcSEcCtD
Bortezomib—Urticaria—Betamethasone—multiple sclerosis	6.26e-05	0.000168	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—multiple sclerosis	6.26e-05	0.000168	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.25e-05	0.000168	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—multiple sclerosis	6.24e-05	0.000168	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—multiple sclerosis	6.23e-05	0.000167	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—multiple sclerosis	6.22e-05	0.000167	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—multiple sclerosis	6.22e-05	0.000167	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—multiple sclerosis	6.22e-05	0.000167	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—multiple sclerosis	6.22e-05	0.000167	CcSEcCtD
Bortezomib—Asthenia—Methylprednisolone—multiple sclerosis	6.21e-05	0.000167	CcSEcCtD
Bortezomib—Insomnia—Prednisone—multiple sclerosis	6.2e-05	0.000166	CcSEcCtD
Bortezomib—Paraesthesia—Prednisone—multiple sclerosis	6.16e-05	0.000165	CcSEcCtD
Bortezomib—Pruritus—Triamcinolone—multiple sclerosis	6.14e-05	0.000165	CcSEcCtD
Bortezomib—Cough—Methotrexate—multiple sclerosis	6.13e-05	0.000164	CcSEcCtD
Bortezomib—Pruritus—Methylprednisolone—multiple sclerosis	6.13e-05	0.000164	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—multiple sclerosis	6.08e-05	0.000163	CcSEcCtD
Bortezomib—Dyspepsia—Prednisone—multiple sclerosis	6.04e-05	0.000162	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—multiple sclerosis	5.98e-05	0.00016	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—multiple sclerosis	5.98e-05	0.00016	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—multiple sclerosis	5.98e-05	0.00016	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—multiple sclerosis	5.96e-05	0.00016	CcSEcCtD
Bortezomib—Rash—Prednisolone—multiple sclerosis	5.95e-05	0.00016	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—multiple sclerosis	5.94e-05	0.00016	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	5.94e-05	0.000159	CcSEcCtD
Bortezomib—Diarrhoea—Methylprednisolone—multiple sclerosis	5.92e-05	0.000159	CcSEcCtD
Bortezomib—Fatigue—Prednisone—multiple sclerosis	5.91e-05	0.000159	CcSEcCtD
Bortezomib—Headache—Prednisolone—multiple sclerosis	5.91e-05	0.000159	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—multiple sclerosis	5.91e-05	0.000159	CcSEcCtD
Bortezomib—Constipation—Prednisone—multiple sclerosis	5.86e-05	0.000157	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—multiple sclerosis	5.78e-05	0.000155	CcSEcCtD
Bortezomib—Dizziness—Triamcinolone—multiple sclerosis	5.74e-05	0.000154	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—multiple sclerosis	5.73e-05	0.000154	CcSEcCtD
Bortezomib—Dizziness—Methylprednisolone—multiple sclerosis	5.73e-05	0.000154	CcSEcCtD
Bortezomib—Infection—Methotrexate—multiple sclerosis	5.69e-05	0.000153	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—multiple sclerosis	5.65e-05	0.000152	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—multiple sclerosis	5.65e-05	0.000152	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—multiple sclerosis	5.65e-05	0.000152	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—multiple sclerosis	5.62e-05	0.000151	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—multiple sclerosis	5.61e-05	0.000151	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—multiple sclerosis	5.61e-05	0.000151	CcSEcCtD
Bortezomib—Nausea—Prednisolone—multiple sclerosis	5.61e-05	0.00015	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—multiple sclerosis	5.57e-05	0.00015	CcSEcCtD
Bortezomib—Pruritus—Betamethasone—multiple sclerosis	5.57e-05	0.00015	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—multiple sclerosis	5.57e-05	0.000149	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—multiple sclerosis	5.54e-05	0.000149	CcSEcCtD
Bortezomib—Vomiting—Triamcinolone—multiple sclerosis	5.52e-05	0.000148	CcSEcCtD
Bortezomib—Vomiting—Methylprednisolone—multiple sclerosis	5.51e-05	0.000148	CcSEcCtD
Bortezomib—Rash—Triamcinolone—multiple sclerosis	5.47e-05	0.000147	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—multiple sclerosis	5.47e-05	0.000147	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—multiple sclerosis	5.46e-05	0.000147	CcSEcCtD
Bortezomib—Rash—Methylprednisolone—multiple sclerosis	5.46e-05	0.000147	CcSEcCtD
Bortezomib—Dermatitis—Methylprednisolone—multiple sclerosis	5.45e-05	0.000146	CcSEcCtD
Bortezomib—Urticaria—Prednisone—multiple sclerosis	5.45e-05	0.000146	CcSEcCtD
Bortezomib—Headache—Triamcinolone—multiple sclerosis	5.44e-05	0.000146	CcSEcCtD
Bortezomib—Headache—Methylprednisolone—multiple sclerosis	5.42e-05	0.000146	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—multiple sclerosis	5.42e-05	0.000146	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—multiple sclerosis	5.42e-05	0.000146	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—multiple sclerosis	5.39e-05	0.000145	CcSEcCtD
Bortezomib—Diarrhoea—Dexamethasone—multiple sclerosis	5.39e-05	0.000145	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—multiple sclerosis	5.36e-05	0.000144	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.22e-05	0.00014	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—multiple sclerosis	5.21e-05	0.00014	CcSEcCtD
Bortezomib—Dizziness—Dexamethasone—multiple sclerosis	5.21e-05	0.00014	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—multiple sclerosis	5.18e-05	0.000139	CcSEcCtD
Bortezomib—Nausea—Triamcinolone—multiple sclerosis	5.15e-05	0.000138	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—multiple sclerosis	5.15e-05	0.000138	CcSEcCtD
Bortezomib—Nausea—Methylprednisolone—multiple sclerosis	5.14e-05	0.000138	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—multiple sclerosis	5.11e-05	0.000137	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisone—multiple sclerosis	5.05e-05	0.000136	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—multiple sclerosis	5.04e-05	0.000135	CcSEcCtD
Bortezomib—Vomiting—Betamethasone—multiple sclerosis	5.01e-05	0.000134	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—multiple sclerosis	5.01e-05	0.000134	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—multiple sclerosis	4.98e-05	0.000134	CcSEcCtD
Bortezomib—Rash—Dexamethasone—multiple sclerosis	4.96e-05	0.000133	CcSEcCtD
Bortezomib—Rash—Betamethasone—multiple sclerosis	4.96e-05	0.000133	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—multiple sclerosis	4.96e-05	0.000133	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—multiple sclerosis	4.96e-05	0.000133	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.95e-05	0.000133	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—multiple sclerosis	4.94e-05	0.000133	CcSEcCtD
Bortezomib—Headache—Betamethasone—multiple sclerosis	4.93e-05	0.000132	CcSEcCtD
Bortezomib—Headache—Dexamethasone—multiple sclerosis	4.93e-05	0.000132	CcSEcCtD
Bortezomib—Asthenia—Prednisone—multiple sclerosis	4.92e-05	0.000132	CcSEcCtD
Bortezomib—Pain—Methotrexate—multiple sclerosis	4.9e-05	0.000132	CcSEcCtD
Bortezomib—Pruritus—Prednisone—multiple sclerosis	4.85e-05	0.00013	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—multiple sclerosis	4.72e-05	0.000127	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—multiple sclerosis	4.69e-05	0.000126	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.69e-05	0.000126	CcSEcCtD
Bortezomib—Nausea—Betamethasone—multiple sclerosis	4.68e-05	0.000126	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—multiple sclerosis	4.68e-05	0.000126	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—multiple sclerosis	4.55e-05	0.000122	CcSEcCtD
Bortezomib—Dizziness—Prednisone—multiple sclerosis	4.53e-05	0.000122	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—multiple sclerosis	4.53e-05	0.000122	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—multiple sclerosis	4.53e-05	0.000122	CcSEcCtD
Bortezomib—Vomiting—Prednisone—multiple sclerosis	4.36e-05	0.000117	CcSEcCtD
Bortezomib—Rash—Prednisone—multiple sclerosis	4.32e-05	0.000116	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—multiple sclerosis	4.32e-05	0.000116	CcSEcCtD
Bortezomib—Headache—Prednisone—multiple sclerosis	4.3e-05	0.000115	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—multiple sclerosis	4.22e-05	0.000113	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—multiple sclerosis	4.11e-05	0.00011	CcSEcCtD
Bortezomib—Nausea—Prednisone—multiple sclerosis	4.07e-05	0.000109	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—multiple sclerosis	4.05e-05	0.000109	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—multiple sclerosis	3.92e-05	0.000105	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—multiple sclerosis	3.79e-05	0.000102	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—multiple sclerosis	3.64e-05	9.78e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—multiple sclerosis	3.61e-05	9.7e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—multiple sclerosis	3.61e-05	9.69e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—multiple sclerosis	3.59e-05	9.64e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—multiple sclerosis	3.4e-05	9.14e-05	CcSEcCtD
Bortezomib—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.99e-05	8.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—TYK2—multiple sclerosis	1.98e-05	8.45e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.97e-05	8.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.96e-05	8.33e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—POMC—multiple sclerosis	1.93e-05	8.23e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SPP1—multiple sclerosis	1.93e-05	8.2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SPP1—multiple sclerosis	1.93e-05	8.2e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SPP1—multiple sclerosis	1.93e-05	8.2e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—POMC—multiple sclerosis	1.92e-05	8.19e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—POMC—multiple sclerosis	1.91e-05	8.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SPP1—multiple sclerosis	1.9e-05	8.09e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCL2—multiple sclerosis	1.89e-05	8.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNG—multiple sclerosis	1.88e-05	8.02e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNG—multiple sclerosis	1.88e-05	8.02e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNG—multiple sclerosis	1.88e-05	8.02e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCL2—multiple sclerosis	1.88e-05	8.01e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.87e-05	7.98e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCR5—multiple sclerosis	1.87e-05	7.98e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCR5—multiple sclerosis	1.87e-05	7.98e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCR5—multiple sclerosis	1.87e-05	7.98e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCL2—multiple sclerosis	1.87e-05	7.97e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—STAT3—multiple sclerosis	1.86e-05	7.92e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TYK2—multiple sclerosis	1.86e-05	7.91e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TYK2—multiple sclerosis	1.86e-05	7.91e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TYK2—multiple sclerosis	1.86e-05	7.91e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNG—multiple sclerosis	1.86e-05	7.91e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.86e-05	7.9e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—STAT3—multiple sclerosis	1.85e-05	7.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCR5—multiple sclerosis	1.85e-05	7.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2RA—multiple sclerosis	1.85e-05	7.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2RA—multiple sclerosis	1.85e-05	7.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2RA—multiple sclerosis	1.85e-05	7.86e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—STAT3—multiple sclerosis	1.84e-05	7.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TYK2—multiple sclerosis	1.83e-05	7.8e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.83e-05	7.79e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.83e-05	7.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2RA—multiple sclerosis	1.82e-05	7.75e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD4—multiple sclerosis	1.82e-05	7.75e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD4—multiple sclerosis	1.82e-05	7.75e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD4—multiple sclerosis	1.82e-05	7.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD4—multiple sclerosis	1.79e-05	7.64e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.79e-05	7.61e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.78e-05	7.57e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—BCHE—multiple sclerosis	1.77e-05	7.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—POMC—multiple sclerosis	1.75e-05	7.46e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—POMC—multiple sclerosis	1.75e-05	7.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—POMC—multiple sclerosis	1.75e-05	7.46e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—POMC—multiple sclerosis	1.73e-05	7.35e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—MYC—multiple sclerosis	1.72e-05	7.32e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TYK2—multiple sclerosis	1.72e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—STAT3—multiple sclerosis	1.72e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MYC—multiple sclerosis	1.71e-05	7.28e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TYK2—multiple sclerosis	1.71e-05	7.28e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—STAT3—multiple sclerosis	1.71e-05	7.27e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—APOE—multiple sclerosis	1.7e-05	7.26e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—APOE—multiple sclerosis	1.7e-05	7.26e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—APOE—multiple sclerosis	1.7e-05	7.26e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MYC—multiple sclerosis	1.7e-05	7.25e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TYK2—multiple sclerosis	1.7e-05	7.24e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—STAT3—multiple sclerosis	1.7e-05	7.24e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—MAPK1—multiple sclerosis	1.69e-05	7.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.69e-05	7.18e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—MAPK1—multiple sclerosis	1.68e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1B—multiple sclerosis	1.68e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1B—multiple sclerosis	1.68e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1B—multiple sclerosis	1.68e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—APOE—multiple sclerosis	1.68e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CD4—multiple sclerosis	1.68e-05	7.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD4—multiple sclerosis	1.68e-05	7.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD4—multiple sclerosis	1.68e-05	7.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—multiple sclerosis	1.67e-05	7.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—multiple sclerosis	1.67e-05	7.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—multiple sclerosis	1.67e-05	7.13e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—MAPK1—multiple sclerosis	1.67e-05	7.13e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.67e-05	7.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1B—multiple sclerosis	1.66e-05	7.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—multiple sclerosis	1.66e-05	7.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—multiple sclerosis	1.65e-05	7.03e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.64e-05	6.96e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.62e-05	6.9e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ALB—multiple sclerosis	1.6e-05	6.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ALB—multiple sclerosis	1.6e-05	6.8e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ALB—multiple sclerosis	1.6e-05	6.8e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MYC—multiple sclerosis	1.59e-05	6.79e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—multiple sclerosis	1.59e-05	6.78e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MYC—multiple sclerosis	1.59e-05	6.76e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—multiple sclerosis	1.58e-05	6.74e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MYC—multiple sclerosis	1.58e-05	6.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—multiple sclerosis	1.58e-05	6.71e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ALB—multiple sclerosis	1.57e-05	6.7e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MAPK1—multiple sclerosis	1.56e-05	6.64e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MAPK1—multiple sclerosis	1.55e-05	6.61e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.55e-05	6.58e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MAPK1—multiple sclerosis	1.55e-05	6.58e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CD80—multiple sclerosis	1.54e-05	6.56e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CD80—multiple sclerosis	1.54e-05	6.56e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CD80—multiple sclerosis	1.54e-05	6.56e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CD80—multiple sclerosis	1.52e-05	6.47e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—POMC—multiple sclerosis	1.46e-05	6.24e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—POMC—multiple sclerosis	1.46e-05	6.24e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—POMC—multiple sclerosis	1.46e-05	6.24e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.45e-05	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—POMC—multiple sclerosis	1.44e-05	6.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL2—multiple sclerosis	1.43e-05	6.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCL2—multiple sclerosis	1.43e-05	6.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL2—multiple sclerosis	1.43e-05	6.1e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—multiple sclerosis	1.43e-05	6.08e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—multiple sclerosis	1.42e-05	6.05e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—multiple sclerosis	1.41e-05	6.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCL2—multiple sclerosis	1.41e-05	6.01e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.41e-05	6.01e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.41e-05	6.01e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—STAT3—multiple sclerosis	1.41e-05	6e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—STAT3—multiple sclerosis	1.41e-05	6e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—STAT3—multiple sclerosis	1.41e-05	6e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—STAT3—multiple sclerosis	1.39e-05	5.92e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.39e-05	5.9e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.38e-05	5.88e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—multiple sclerosis	1.35e-05	5.76e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—multiple sclerosis	1.35e-05	5.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—multiple sclerosis	1.34e-05	5.7e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.33e-05	5.65e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.32e-05	5.62e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TYK2—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TYK2—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TYK2—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—STAT3—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—STAT3—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—STAT3—multiple sclerosis	1.3e-05	5.54e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—multiple sclerosis	1.3e-05	5.53e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—multiple sclerosis	1.29e-05	5.5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.29e-05	5.5e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—multiple sclerosis	1.29e-05	5.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—multiple sclerosis	1.28e-05	5.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TYK2—multiple sclerosis	1.28e-05	5.46e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—STAT3—multiple sclerosis	1.28e-05	5.46e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MAPK1—multiple sclerosis	1.28e-05	5.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MAPK1—multiple sclerosis	1.28e-05	5.45e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MAPK1—multiple sclerosis	1.28e-05	5.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MAPK1—multiple sclerosis	1.26e-05	5.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.26e-05	5.36e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—BCHE—multiple sclerosis	1.25e-05	5.31e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.21e-05	5.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—multiple sclerosis	1.21e-05	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—multiple sclerosis	1.21e-05	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—multiple sclerosis	1.21e-05	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—multiple sclerosis	1.21e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—multiple sclerosis	1.21e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—multiple sclerosis	1.21e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—STAT3—multiple sclerosis	1.2e-05	5.12e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—multiple sclerosis	1.2e-05	5.11e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—STAT3—multiple sclerosis	1.2e-05	5.09e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—multiple sclerosis	1.19e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—multiple sclerosis	1.19e-05	5.07e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—STAT3—multiple sclerosis	1.19e-05	5.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—multiple sclerosis	1.19e-05	5.06e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—multiple sclerosis	1.19e-05	5.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.18e-05	5.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MAPK1—multiple sclerosis	1.18e-05	5.04e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MAPK1—multiple sclerosis	1.18e-05	5.04e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MAPK1—multiple sclerosis	1.18e-05	5.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MAPK1—multiple sclerosis	1.17e-05	4.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.14e-05	4.87e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—multiple sclerosis	1.12e-05	4.76e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—multiple sclerosis	1.11e-05	4.74e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—multiple sclerosis	1.11e-05	4.73e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—multiple sclerosis	1.11e-05	4.72e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—multiple sclerosis	1.11e-05	4.71e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—multiple sclerosis	1.1e-05	4.7e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK1—multiple sclerosis	1.09e-05	4.65e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MAPK1—multiple sclerosis	1.09e-05	4.63e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—multiple sclerosis	1.08e-05	4.61e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—multiple sclerosis	1.08e-05	4.61e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—multiple sclerosis	1.08e-05	4.61e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK1—multiple sclerosis	1.08e-05	4.61e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.08e-05	4.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.08e-05	4.6e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.07e-05	4.58e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.07e-05	4.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—multiple sclerosis	1.07e-05	4.54e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—multiple sclerosis	1.07e-05	4.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—multiple sclerosis	1.02e-05	4.36e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—multiple sclerosis	1.02e-05	4.36e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—multiple sclerosis	1.02e-05	4.36e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.02e-05	4.35e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—multiple sclerosis	1.01e-05	4.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.85e-06	4.2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—multiple sclerosis	9.84e-06	4.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—multiple sclerosis	9.84e-06	4.19e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—multiple sclerosis	9.84e-06	4.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—multiple sclerosis	9.7e-06	4.13e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.39e-06	4e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.31e-06	3.97e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.23e-06	3.93e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—POMC—multiple sclerosis	9.15e-06	3.9e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—multiple sclerosis	9.11e-06	3.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—multiple sclerosis	9.11e-06	3.88e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—multiple sclerosis	9.11e-06	3.88e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—multiple sclerosis	9.08e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—multiple sclerosis	9.08e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—multiple sclerosis	9.08e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—multiple sclerosis	8.98e-06	3.82e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—multiple sclerosis	8.96e-06	3.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—multiple sclerosis	8.46e-06	3.6e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—multiple sclerosis	8.46e-06	3.6e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—multiple sclerosis	8.46e-06	3.6e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—multiple sclerosis	8.44e-06	3.6e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—multiple sclerosis	8.44e-06	3.6e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—multiple sclerosis	8.44e-06	3.6e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.42e-06	3.59e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—multiple sclerosis	8.39e-06	3.58e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—multiple sclerosis	8.35e-06	3.56e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—multiple sclerosis	8.34e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—multiple sclerosis	8.34e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—multiple sclerosis	8.32e-06	3.54e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—multiple sclerosis	8.31e-06	3.54e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK1—multiple sclerosis	8.28e-06	3.53e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK1—multiple sclerosis	8.28e-06	3.53e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK1—multiple sclerosis	8.28e-06	3.53e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK1—multiple sclerosis	8.16e-06	3.48e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BCHE—multiple sclerosis	7.96e-06	3.39e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—multiple sclerosis	7.51e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—multiple sclerosis	6.88e-06	2.93e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—multiple sclerosis	6.45e-06	2.75e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—multiple sclerosis	6.36e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—multiple sclerosis	6.36e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—multiple sclerosis	6.36e-06	2.71e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—multiple sclerosis	6.27e-06	2.67e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—multiple sclerosis	6.14e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.14e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—multiple sclerosis	5.91e-06	2.52e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—multiple sclerosis	5.88e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—multiple sclerosis	5.65e-06	2.41e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—multiple sclerosis	5.6e-06	2.39e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—multiple sclerosis	5.39e-06	2.3e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—multiple sclerosis	5.28e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—multiple sclerosis	4.85e-06	2.07e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—multiple sclerosis	4.81e-06	2.05e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—multiple sclerosis	4.81e-06	2.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—multiple sclerosis	4.79e-06	2.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—multiple sclerosis	4.42e-06	1.88e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—multiple sclerosis	4.39e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—multiple sclerosis	4.11e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—multiple sclerosis	3.75e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—multiple sclerosis	3.69e-06	1.57e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—multiple sclerosis	3.17e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—multiple sclerosis	2.89e-06	1.23e-05	CbGpPWpGaD
